YYC 405
Alternative Names: YYC-405; YYC405-TLatest Information Update: 09 Feb 2022
At a glance
- Originator Yooyoung Pharmaceutical
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus